Acrivastine|87848-99-5|(阿伐斯汀; BW825C)-陌孚医药/Medlife

您当前的位置：

Acrivastine (Synonyms: 阿伐斯汀; BW825C)

目录号: PL14963 纯度: ≥99%

CAS No. :87848-99-5

商品编号	规格	价格	会员价
PL14963-10mg	10mg	¥680.00	请登录
PL14963-50mg	50mg	¥2349.09	请登录
PL14963-100mg	100mg	¥3338.18	请登录
PL14963-200mg	200mg	询价	询价
PL14963-500mg	500mg	询价	询价
PL14963-10mM*1mLinDMSO	10mM*1mLinDMSO	¥748.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Acrivastine
中文别名	阿伐斯汀;(E)-3-[6-[(E)-1-(4-甲基苯基)-3-吡咯烷-1-基丙-1-烯基]吡啶-2-基]-2-丙烯酸;阿伐司丁;阿伐司汀;(E,E)-3-[6-[1-(对甲苯基)-3-吡咯烷-1-基-1-丙烯基]-2-吡啶基]丙烯酸;Acrivastine 阿伐斯汀;阿伐斯汀标准品
英文名称	Acrivastine
英文别名	Acrivastine;(e)-3-[6-[(e)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid;Acrivastin;BW-270C;BW-825C;BW-A825C;(E)-3-[6-[(E)-1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]propenoic acid;BW825C;(E,E)-3-[6-[1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid;Acrivastina;Acrivastinum;BW A825C;Semprex;(E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid;BenadrylAlIergyReIie;Acrivastinum [Latin];BW 825C;Acrivastina [Spanish];Acrivastine [USAN:INN:BAN];A20F9XAI7W;C22H24N2O2;(E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure;2-Propenoic acid, 3-(6-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-2-pyridinyl)-, (E,E)-;(2E)-3-{6-[(1E)-1-(;(E)-3-[6-[(E)-1-(4-Methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
Cas No.	87848-99-5
分子式	C₂₂H₂₄N₂O₂
分子量	348.44
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	Acrivastine (BW825C) 是用于研究过敏性鼻炎的短效histamine 1受体拮抗剂。
生物活性	Acrivastine (BW825C) is a short acting histamine 1 receptor antagonist for the treatment of allergic rhinitis.
性状	Solid
体内研究(In Vivo)	Acrivastine (usually 8mg three times daily) is an effective and well tolerated antihistamine in the treatment of chronic urticaria and allergic rhinitis. Acrivastine is more effective than placebo and similar in efficacy to clemastine or terfenadine in the treatment of seasonal allergic rhinitis. In the treatment of dermatoses in which histamine has a pathogenetic role, the efficacy of acrivastine is superior to that of placebo and similar to that of usual dosages of clemastine, hydroxyzine, chlorpheniramine, cyproheptadine or terfenadine. Acrivastine causes less drowsiness than clemastine, the incidence of adverse effects being indistinguishable from that with placebo or terfenadine. Both 4 mg and 8 mg acrivastine alleviate the symptoms of seasonal allergic rhinitis with significant improvements in the symptom scores for sneezing, running nose and the calculated overall score
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40. [2]. Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4.

溶解度数据	In Vitro: DMSO : 50 mg/mL (143.50 mM; Need ultrasonic)H₂O : 1 mg/mL (2.87 mM; ultrasonic and warming and heat to 80°C)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation